OrthogenRx, Inc.

OrthogenRxModel GenVisc 850 -5-Injection Hyaluronic Acid Regimen

SHARE

Knee pain caused by osteoarthritis is suffered by millions of people worldwide1. GenVisc 850, a 5-injection hyaluronic acid from OrthogenRx, may help relieve OA-related knee pain in patients who are unresponsive to non-pharmacologic therapy and simple analgesics. GenVisc 850 is approved for 5 injections, but some patients may benefit from as few as 3 injections.

Most popular related searches

Proven

  • GenVisc 850 is approved in 64 countries with over 45 million syringes distributed worldwide
  • GenVisc 850 has the largest and longest duration double blind clinical study of hyaluronic acids for knee osteoarthritis.
  • GenVisc 850 has been published in over 30 clinical studies.

Safe

  • Safe as saline placebo
  • Free of avian proteins
  • Demonstrated safe for repeat injection cycles

Effective

  • Provides significant pain relief with results that last
  • Demonstrated improvement in pain relief up to 30 weeks post first injection cycle
  • Demonstrated improvement of total WOMAC index at 30 weeks: Pain, stiffness and functional capacity